DaVita (NYSE:DVA) CFO Sells $9,887,579.10 in Stock

DaVita Inc. (NYSE:DVA) CFO Joel Ackerman sold 51,471 shares of the stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the sale, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. This represents a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

DaVita Trading Up 0.1%

Shares of DVA stock traded up $0.22 during trading hours on Monday, hitting $198.87. The company’s stock had a trading volume of 1,065,673 shares, compared to its average volume of 1,018,599. The business has a fifty day moving average of $153.03 and a 200-day moving average of $132.70. The stock has a market cap of $12.77 billion, a price-to-earnings ratio of 18.45, a P/E/G ratio of 0.65 and a beta of 0.84. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $202.13.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.33 by $0.54. The business had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period in the prior year, the business earned $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities analysts expect that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on DVA. Barclays increased their price target on shares of DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research report on Thursday. Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft upgraded shares of DaVita from a “hold” rating to a “buy” rating and raised their target price for the stock from $126.00 to $220.00 in a research report on Wednesday, May 6th. Truist Financial raised their target price on shares of DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research report on Friday. Finally, Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $199.17.

Hedge Funds Weigh In On DaVita

A number of hedge funds have recently made changes to their positions in DVA. NewEdge Advisors LLC boosted its holdings in shares of DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after purchasing an additional 88 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of DaVita by 19.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after purchasing an additional 28,739 shares during the last quarter. Cerity Partners LLC boosted its holdings in shares of DaVita by 7.0% in the 2nd quarter. Cerity Partners LLC now owns 2,638 shares of the company’s stock valued at $376,000 after purchasing an additional 172 shares during the last quarter. Bank of Nova Scotia boosted its holdings in shares of DaVita by 3.8% in the 2nd quarter. Bank of Nova Scotia now owns 4,813 shares of the company’s stock valued at $686,000 after purchasing an additional 176 shares during the last quarter. Finally, Natixis boosted its holdings in shares of DaVita by 80.9% in the 2nd quarter. Natixis now owns 7,297 shares of the company’s stock valued at $1,039,000 after purchasing an additional 3,264 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.